Actively Recruiting

Age: 18Years - 65Years
All Genders
NCT05976919

Evaluating Treatable Traits Across the Spectrum of Chronic Obstructive Airways Disease

Led by University of Leeds · Updated on 2025-03-30

100

Participants Needed

1

Research Sites

95 weeks

Total Duration

On this page

Sponsors

U

University of Leeds

Lead Sponsor

T

The Leeds Teaching Hospitals NHS Trust

Collaborating Sponsor

AI-Summary

What this Trial Is About

Respiratory disease affects one in five people and is a leading cause of global morbidity and mortality. Chronic obstructive airways diseases encompass conditions characterised by expiratory airflow limitation, exertional dyspnoea, activity limitation and impaired quality of life. The most common conditions include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, cystic fibrosis and primary ciliary dyskinesia. In recent years, there has been concerted effort in the scientific and respiratory medicine community to improve the diagnosis and management of chronic obstructive airways diseases using personalised or precision medicine (i.e., tailoring therapies and interventions according to specific "treatable traits") and identifying phenotypes or endotypes using validated biomarkers. To date, however, research in this setting has primarily focussed on people with COPD and asthma, with limited studies in other forms of chronic obstructive airways diseases. The aim of this study is therefore two-fold; first, to compare pulmonary physiology (i.e., large and small airway involvement) and extra-pulmonary manifestations across the spectrum of chronic obstructive airways, and second, to determine how disease-specific treatable traits associate with physical activity and health-related quality of life.

CONDITIONS

Official Title

Evaluating Treatable Traits Across the Spectrum of Chronic Obstructive Airways Disease

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Prior diagnosis of airways disease in accordance with European Respiratory Society guidelines
  • Non-smokers or ex-smokers (pack history recorded)
  • Male or female aged 18 to 65 years
  • Ability to provide written informed consent
  • Full understanding of spoken and written English
  • Cystic fibrosis patients on triple CFTR modulators (90% of cohort)
  • Cystic fibrosis patients not on CFTR modulators
  • Healthy controls with no respiratory symptoms, no inhaler use, and no history of respiratory disease
Not Eligible

You will not qualify if you...

  • Severe exacerbation requiring hospital admission or oral corticosteroids in the past two months
  • Contraindications to cardio-pulmonary exercise testing or submaximal exercise testing
  • Contraindications to pulmonary function testing
  • Contraindications to dual energy x-ray (DEXA) scanning, including pregnancy, recent contrast media use, or subject weight
  • Non-ambulant or musculoskeletal impairments affecting daily activities or exercise testing
  • Significant cognitive impairment preventing consent or safe test performance
  • Currently receiving oxygen therapy
  • Unable to provide consent
  • Infection with Burkholderia Cepacia Complex, mycobacterium tuberculosis, or mycobacterium abscessus
  • Lung transplantation
  • Diagnosis of cardiovascular disease
  • Abnormal blood tests such as anemia or moderate/severe renal failure

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Leeds

Leeds, Leeds, United Kingdom, LS2 9JT

Actively Recruiting

Loading map...

Research Team

O

Oliver Price, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluating Treatable Traits Across the Spectrum of Chronic Obstructive Airways Disease | DecenTrialz